Who are aTyr Pharma, Inc.'s main suppliers?

aTyr Pharma, Inc. (ATYR) key suppliers include: CDMOS, CROS, INVESTIGATIVE-SITES, LABORATORY-SUPPLIES. View the full supplier network at chainsifter.com/chain/ATYR.

Who are aTyr Pharma, Inc.'s major customers?

aTyr Pharma, Inc. (ATYR) key customers include: Myriad Genetics, Inc., Myriad Genetics, Inc., PANGU-BIOPHARMA-LIMITED. View the full customer network at chainsifter.com/chain/ATYR.

What sector is aTyr Pharma, Inc. in?

aTyr Pharma, Inc. (ATYR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

aTyr Pharma, Inc. Supplier List (ATYR): 4 Verified Suppliers

4Suppliers

3Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

aTyr Pharma, Inc. (ATYR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

11Total relationships

1Distinct source URLs

7High confidence

0.815Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

aTyr Pharma, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CDMOS	CDMOS	90%	we outsource our manufacturing of clinical trial materials to CDMOs
CROS	CROS	90%	We primarily outsource our clinical trial administration to CROs
INVESTIGATIVE-SITES	INVESTIGATIVE-SITES	80%	costs incurred under clinical trial agreements with CROs and investigative sites
LABORATORY-SUPPLIES	LABORATORY-SUPPLIES	70%	costs for laboratory supplies

aTyr Pharma, Inc. Customers

Ticker	Name	Confidence	Evidence
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from ATYR graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from ATYR graph: duce preclinical, clinical and comm…
MYGN	Myriad Genetics, Inc.	72%	duce preclinical, clinical and commercial supplies of our product candidates. Other than some internal capacity to support preclinical activities, we do not have, nor do we plan to acquire, the infra…
PANGU-BIOPHARMA-LIMITED	PANGU-BIOPHARMA-LIMITED	62%	duce preclinical, clinical and commercial supplies of our product candidates. Other than some internal capacity to support preclinical activities, we do not have, nor do we plan to acquire, the infra…

aTyr Pharma, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ATYR-DEBT	Debt stack $5.8M	90%	Market cache reports total debt of $5.8M.
ATYR-DEBT-7966	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2015-12-31.
ATYR-DEBT-7965	Warrants outstanding: 263000	90%	xbrl warrant detail from xbrl 2017-12-31.

aTyr Pharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for aTyr Pharma, Inc..

aTyr Pharma, Inc. Ownership

Holder	Name	Confidence	Evidence
ATYR-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 113 tracked holders.

aTyr Pharma, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
TEM	Tempus AI, Inc.	100.00	2
JANX	Janux Therapeutics, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
DNLI	Denali Therapeutics Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
BNTC	Benitec Biopharma Inc.	100.00	2
ELVN	Enliven Therapeutics, Inc.	100.00	2
BIAF	bioAffinity Technologies, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
IMNM	Immunome, Inc.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
TPST	Tempest Therapeutics, Inc.	100.00	2
GH	Guardant Health, Inc.	100.00	2
KDK	Kodiak AI, Inc.	100.00	2
IRD	Opus Genetics, Inc.	100.00	2

aTyr Pharma, Inc. Supply Chain